Han Kun advises 3SBio in landmark Pfizer licensing deal
Chinese biopharmaceutical company 3SBio has reached a milestone agreement with US giant Pfizer, licensing its developed PD-1/VEGF bispecific antibody drug, SSGJ-707, in a deal worth more than USD6 billion. Pharmaceutical giant Pfizer will pay an …